The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...